Details of the Drug

General Information of Drug (ID: DMINO7Z)

Drug Name
Perhexiline
Synonyms
Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1]
Therapeutic Class
Vasodilator Agents
Affected Organisms
Humans and other mammals
ATC Code
C08EX02: Perhexiline
C08EX: Other non-selective calcium channel blockers
C08E: NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
C08: CALCIUM CHANNEL BLOCKERS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 277.5
Logarithm of the Partition Coefficient (xlogp) 6.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
73.5% of drug becomes completely available to its intended biological destination(s) [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 6 days [4]
Metabolism
The drug is metabolized via the cytochrome P450 2D6 (CY P450 2D6) []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.01818 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.00006 mg/mL [2]
Chemical Identifiers
Formula
C19H35N
IUPAC Name
2-(2,2-dicyclohexylethyl)piperidine
Canonical SMILES
C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
InChI
InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
InChIKey
CYXKNKQEMFBLER-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4746
ChEBI ID
CHEMBL75880
CAS Number
39648-47-0
UNII
KU65374X44
DrugBank ID
DB01074
TTD ID
D00SBN
INTEDE ID
DR1260
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carnitine O-palmitoyltransferase I (CPT1B) TTDL0NY CPT1B_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [6]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [7]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [7]
AP-1 complex subunit sigma-1A (AP1S1) OTQ2H8DN AP1S1_HUMAN Gene/Protein Processing [8]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Gene/Protein Processing [7]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Gene/Protein Processing [8]
Lysophospholipase D GDPD3 (GDPD3) OTOHM9QM GDPD3_HUMAN Gene/Protein Processing [7]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Gene/Protein Processing [8]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Gene/Protein Processing [7]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Gene/Protein Processing [9]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
7 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
8 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
9 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.